XASX
SIG
Market cap22bUSD
Jun 18, Last price
2.81AUD
1D
0.00%
1Q
1.08%
Jan 2017
117.83%
IPO
-23.76%
Name
Sigma Healthcare Ltd
Chart & Performance
P/E
—
P/S
6.63
EPS
—
Div Yield, %
0.46%
Shrs. gr., 5y
0.01%
Rev. gr., 5y
8.57%
Revenues
4.89b
+47.32%
Net income
-14m
L
CFO
-316m
L
Dividend
Sep 02, 20250.013 AUD/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Sigma Healthcare Limited, together with its various operating divisions, primarily engages in the wholesale supply and distribution of pharmaceutical goods across Australia. The company also manages a significant network of approximately 1,200 retail pharmacies, encompassing both independent outlets and prominent brands such as Amcal, Discount Drug Stores, Guardian, WholeLife, and PharmaSave. Beyond retail, its comprehensive service portfolio includes wholesale provisions for hospital pharmacies, as well as crucial dose administration aid services delivered to the aged care sector, community pharmacies, and directly to individuals in their homes. Furthermore, Sigma offers advanced technology solutions and data analytics, alongside product development and support for its range of private and exclusive label products. It is also a key supplier of medical consumables and devices to a broad spectrum of customers, from pharmacies and aged care facilities to hospitals and clinics. In addition, the company provides contract logistics services to pharmaceutical manufacturers and other supply partners. Established in 1912, Sigma Healthcare Limited maintains its corporate headquarters in Rowville, Australia.
Valuation
Title AUD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2025‑01 | 2024‑01 | 2023‑01 | 2022‑01 | 2021‑01 | 2020‑01 | 2019‑01 | 2018‑01 | 2017‑01 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||